1991
A Phase II Trial of Cyclosporin A in the Treatment of Refractory Metastatic Colorectal Cancer
Murren J, Ganpule S, Sarris A, Durivage H, Davis C, Makuch R, Handschumacher R, Marsh J. A Phase II Trial of Cyclosporin A in the Treatment of Refractory Metastatic Colorectal Cancer. American Journal Of Clinical Oncology 1991, 14: 208-217. PMID: 2031507, DOI: 10.1097/00000421-199106000-00007.Peer-Reviewed Original ResearchConceptsPhase II trialCyclosporin AII trialColorectal cancerEuropean Cooperative Oncology Group performance statusRefractory metastatic colorectal cancerSignificant toxicityRefractory colorectal cancerMetastatic colorectal cancerFlu-like symptomsMeasurable diseaseStable diseaseStarting doseColorectal malignancyObjective responsePerformance statusImmunosuppressive agentsInitial doseDose reductionColon cancerPatientsHuman neoplasmsExperimental modelCancerDose
1983
Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients
Kinsella T, Glaubiger D, Diesseroth A, Makuch R, Waller B, Pizzo P, Glatstein E. Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients. International Journal Of Radiation Oncology • Biology • Physics 1983, 9: 1955-1960. PMID: 9463099, DOI: 10.1016/0360-3016(83)90368-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgranulocytosisAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBone NeoplasmsChildCombined Modality TherapyCyclophosphamideDactinomycinDisease-Free SurvivalFemaleHumansLung NeoplasmsMaleNeoplasm Recurrence, LocalSarcoma, EwingVincristineWhole-Body IrradiationConceptsAutologous bone marrow infusionHigh-risk Ewing's sarcoma patientsTotal body irradiationEwing's sarcoma patientsLow-dose total body irradiationComplete clinical responseSarcoma patientsGranulocyte recoveryClinical responseModality therapyModality protocolMedian disease-free intervalMicroscopic systemic diseaseMonths of relapseBone marrow infusionCells/mm3Disease-free intervalPoor prognosis groupOnly distant metastasesTotal granulocyte countConsolidative therapyInduction therapyInitial relapseMaintenance chemotherapySecond relapse
1981
Prognostic Implications of Stage of Disease and Sites of Metastases in Patients with Small Cell Carcinoma of the Lung Treated with Intensive Combination Chemotherapy1,2
Ihde D, Makuch R, Carney D, Bunn P, Cohen M, Matthews M, Minna J. Prognostic Implications of Stage of Disease and Sites of Metastases in Patients with Small Cell Carcinoma of the Lung Treated with Intensive Combination Chemotherapy1,2. American Journal Of Respiratory And Critical Care Medicine 1981, 123: 500-7. PMID: 6263137, DOI: 10.1164/arrd.1981.123.5.500.Peer-Reviewed Original ResearchConceptsSmall cell carcinomaExtensive diseaseCentral nervous systemLimited diseaseCell carcinomaBone marrowNervous systemIntensive induction chemotherapyInvolvement of boneSite of metastasisSoft tissueRadionuclide boneAggressive chemotherapyInduction chemotherapyChest roentgenogramMetastatic diseaseUntreated patientsLiver biopsyStaging procedureDistant metastasisFiberoptic bronchoscopyOpposite lungPrognostic implicationsPhysical examinationPretreatment stagingInfluence of prognostic factors on survival in Ewing's sarcoma.
Glaubiger D, Makuch R, Schwarz J. Influence of prognostic factors on survival in Ewing's sarcoma. National Cancer Institute Monograph 1981, 285-8. PMID: 7300894.Peer-Reviewed Original ResearchConceptsPrimary diseaseEwing's sarcomaTreatment groupsSerum lactate dehydrogenase levelIntensive adjuvant chemotherapySystemic chemotherapy regimensLactate dehydrogenase levelsNumber of patientsSignificant differencesNational Cancer InstituteRecent treatment regimensAdjuvant chemotherapyChemotherapy regimensPrognostic factorsPrimary lesionTreatment regimensLDH levelsMetastatic statusSurvival resultsDehydrogenase levelsTreatment protocolLocal irradiationCancer InstituteSarcomaPrimary site